Verisante Notches First Sales of Aura Skin Cancer Detection Device | GenomeWeb

Verisante Technology said this week that it has received the first orders for its Raman spectroscopy-based Aura skin cancer detection system and plans an initial production run of 10 devices to be placed in Canada and Europe.

The company will begin shipping the devices this month to its Canadian distributor Clarion and Laserwelt, its distributor for Germany, Austria, and Liechtenstein.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.